2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2021
High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests
Zuo T, Levi AW, Lin Q, Abi-Raad R, Adeniran AJ, Cai G. High-Risk Human Papillomavirus Testing, Genotyping, and Histopathologic Follow-up in Women With Abnormal Glandular Cells on Papanicolaou Tests. American Journal Of Clinical Pathology 2021, 156: 569-576. PMID: 33728437, DOI: 10.1093/ajcp/aqaa265.Peer-Reviewed Original ResearchConceptsPositive hrHPV resultsCervical intraepithelial neoplasiaHrHPV resultsHrHPV testingCIN2-3Intraepithelial neoplasiaPapanicolaou testCervical carcinomaHigh risk human papillomavirus statusHigh-risk human papillomavirus (hrHPV) testingHigh-grade cervical intraepithelial neoplasiaLow-grade cervical intraepithelial neoplasiaHuman papillomavirus testingHuman papillomavirus (HPV) statusManagement of patientsAbnormal glandular cellsHPV genotypesHPV subtypesAGC casesPap testFollow-upHistologic followHigh lesionsType 16Reactive changes
2014
Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection
Brandsma JL, Harigopal M, Kiviat NB, Sun Y, Deng Y, Zelterman D, Lizardi PM, Shabanova VS, Levi A, Yaping T, Hu X, Feng Q. Methylation of Twelve CpGs in Human Papillomavirus Type 16 (HPV16) as an Informative Biomarker for the Triage of Women Positive for HPV16 Infection. Cancer Prevention Research 2014, 7: 526-533. PMID: 24556390, DOI: 10.1158/1940-6207.capr-13-0354.Peer-Reviewed Original ResearchConceptsCervical intraepithelial neoplasiaCytology samplesCutoff scoreColposcopy of womenCervical cancer preventionManagement of womenDetection of CIN3Cervical cytology samplesHuman papillomavirus type 16Human papillomavirus type 16 DNAMethylation biomarkersPapillomavirus type 16Histologic severityIntraepithelial neoplasiaCervical cancerHPV16 infectionCancer preventionDNA bisulfite sequencingType 16Prognostic potentialAccurate biomarkersProspective biomarkersScreening testInformative biomarkersBiomarkers